What should I do if I become resistant to Nilotinib?

Nilotinib (Nilotinib) is a very effective drug for the treatment of patients who are sensitive or resistant to imatinib. Despite highly successful hematological and cytogenetic responses in patients treated with nilotinib, cases of resistance to nilotinib have been observed in recent years. By studying the potential mechanisms of nilotinib resistance and providing new targets for the treatment of chronic myelogenous leukemia (CML).

Multidrug resistance remains a significant obstacle to successful chemotherapy. Identifying possible mechanisms of resistance and the ability to overcome resistance have the potential to improve chemotherapy. In nilotinib-resistant cells, anti-apoptotic BCR/ABL, GCS and SK-1 genes and MRP1 transporter genes were up-regulated, while apoptotic Bax and CerS1 genes were down-regulated. There are no mutations in the nilotinib binding region of BCR/ABL in drug-resistant cells. Inhibition of GCS and SK-1 restored nilotinib sensitivity. In addition to inhibiting BCR/ABL, targeting proteins involved in nilotinib resistance may be a better approach to treat CML. Everyone’s constitution is different and their resistance to drugs is also different. If drug resistance develops after using the drug, please inform your doctor in time and do not adjust the drug dosage yourself.

The original drug Nilotinib is marketed in China under the name Nilotinib and is covered by medical insurance, but reimbursement is limited to patients who meet the indications. SpecificationsThe price of 150mg*120 tablets per box may be around 9,000 yuan. The Indian version of Nilotinib is available overseas. The price of Nilotinib's original drug, 150mg*28 capsules per box, may be around RMB 1,000 (the price may fluctuate due to exchange rates). The ingredients of the original drug sold domestically and abroad are basically the same. Currently, there is no generic version of Nilotinib produced and launched. For more drug information and specific prices, please consult Yaode Medical Consultants.